CClinicalTrials.gg
Status unknownNCT01113359Updated Apr 29, 2010

The Link Between Human Cytomegalovirus (HCMV) and Hypertension

An observational study in HCMV Infection and Hypertension, sponsored by Beijing Chao Yang Hospital. Status unknown at 1 site in China. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-04-29.

Sponsored by Beijing Chao Yang Hospital · Observational

The sponsor has not verified this record recently (last verified Apr 2010), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
300
Ages
30 Years to 60 Years
Sex
All
01

Study summary

It has been reported that mouse cytomegalovirus infection alone can elevate the blood pressure in mice. Since HCMV has uniquely evolved with its human host, with little genetic similarity to the animal CMV counterparts, and it only replicates in human, an epidemiological study is required to define the relevance of HCMV infection and expression of hcmv-miRNA-UL112 to the pathogenesis of essential hypertension.

The investigators found that hcmv-miR-UL112, a human cytomegalovirus (HCMV)-encoded miRNA, was highly expressed in the hypertensive patients. Among the top miRNA target predictions, the investigators demonstrate that IRF-1 is a direct target gene of hcmv-miR-UL112, along with MICB that has been previously reported. Both IRF-1 and MICB play critical roles in immuno/inflammatory and anti-infection response. Thus, the investigators speculated that IRF-1 and MICB repression by hcmv-miR-UL112 could be considered a unifying mechanism that evades the host response at several levels: antiviral, inflammatory, and immune. In addition, there is an increasing evidence that IRF-1 may be important in apoptosis, angiogenesis, neointima formation and the pathogenesis of vascular diseases. IRF-1 can up-regulate angiotensin II type 2 receptor (AGTR2) that exerts antiproliferative and proapoptotic actions and affects regulation of blood pressure. It has been reported that the targeted disruption of the mouse AGTR2 gene resulted in a significant increase in blood pressure and increased sensitivity to angiotensin II. The nitric oxide synthase expression and NO synthesis in macrophages and distinct cardiomyocytes are induced and controlled by IRF-1 in response to inflammation, important steps in vascular biology that may improve endothelial function and inhibit smooth muscle cell migration, and a key pathophysiological event in hypertension. Collectively, these reports support a strong relationship between IRF-1 regulation and hypertension, indicating a potential role of hcmv-miR-UL112 and HCMV infection in the pathogenesis of hypertension.Thus, the investigators want to investigate the potential link between HCMV infection and essential hypertension.

02

Conditions studied

  • HCMV Infection
  • Hypertension

Keywords

  • HCMV infection
  • Hypertension
  • The Potential Link Between HCMV Infection and Essential Hypertension
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 300 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Beijing Chao Yang Hospital is the lead sponsor of 135 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

essential hypertensive patients:

Inclusion criteria

  • Patients with essential hypertension are assessed for potential secondary causes, for the severity of hypertension, other risk factors and for end-organ damage
  • Aged between 30 to 60 years
  • Untreated (whole day average > 140/90 mmHg) or treated hypertension whole-day average \< 140/85), as determined by 24-hour blood pressure monitoring.

Exclusion criteria

Exclusion Criteria:

  • Cancer
  • Diabetes
  • Smoking
  • Renal failure
  • Stroke
  • Peripheral artery disease
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Biospecimen retention
Samples without dna

Groups and cohorts

  • study group

    hypertensive patients

  • control group

    healthy volunteer

06

What researchers measure

Primary outcomes

  1. The positive rate of HCMV infection in hypertensive patients and healthy control

    Time frame: 1 month

Secondary outcomes

  1. HCMV copies number per ml plasma of hypertensive patients and healthy controls

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • Jun Cai
    Beijing, Chaoyang 100020, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01113359
Lead sponsor
Beijing Chao Yang Hospital
First posted
Apr 29, 2010
Start date
Apr 2010
Primary completion
May 2010 (estimated)
Completion
May 2010 (estimated)
Last update
Apr 29, 2010

Study contacts

Xin-Chun Yang, MD
principal investigator · Beijing Chao Yang Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion